We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 06, 2021

Addition of Everolimus to First-Line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators

JAMA Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial
JAMA Oncol 2021 Aug 26;[EPub Ahead of Print], Y Fan, T Sun, Z Shao, Q Zhang, Q Ouyang, Z Tong, S Wang, Y Luo, Y Teng, X Wang, S Wang, Q Liu, J Feng, K Shen, Y Song, J Wang, F Ma, Q Li, P Zhang, B Xu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading